

Filed On Behalf Of:

Novartis AG

By:

Nicholas N. Kallas
NKallas@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,
Petitioner,

v.

NOVARTIS AG,
Patent Owner.

Case IPR2016-00084
Patent 5,665,772

**UPDATE TO PATENT OWNER'S MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8(a)(3)**

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(3), Novartis AG (“Novartis” or “Patent Owner”) submits the following update to its November 13, 2015 Mandatory Notices (Paper No. 5).

REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)

The real party-in-interest information has not changed.

RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)

The Patent Owner hereby notifies the Board of changes in the matters related to the present proceedings pursuant to 37 C.F.R. § 42.8(b)(2).

U.S. Patent No. 5,665,772 (“the ’772 Patent”) is being asserted in the following patent infringement lawsuits: (1) Novartis Pharm. Corp. et al. v. Breckenridge Pharm., Inc., No. 14-1043-RGA (D. Del.); (2) Novartis Pharm. Corp. et al. v. Roxane Labs., Inc., No. 14-1196-RGA (D. Del.); (3) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 14-1289-RGA (D. Del.); (4) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 14-1494-RGA (D. Del.); (5) Novartis Pharm. Corp. et al. v. Roxane Labs., Inc., No. 14-1508-RGA (D. Del.); (6) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 15-78-RGA (D. Del.); (7) Novartis Pharm. Corp. et al. v. Roxane Labs., Inc., No. 15-128-RGA (D. Del.); and (8) Novartis Pharm. Corp. et al. v. Breckenridge Pharm., Inc., No. 16-431-RGA (D. Del.).

The '772 Patent is also involved in the following *Inter Partes* Review Proceedings: (1) Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-01059 (P.T.A.B.); (2) Novartis AG v. Breckenridge Pharm., Inc., *Inter Partes* Review No. 2016-01023 (P.T.A.B.); (3) Novartis AG v. Roxane Laboratories, Inc., *Inter Partes* Review No. 2016-01102; and (4) Novartis AG v. Breckenridge Pharm., Inc., *Inter Partes* Review No. 2016-01103 (P.T.A.B.).

Other proceedings involving different patents that cover the same products as the proceedings above include: (1) Novartis Pharm. Corp. et al. v. Roxane Labs., Inc., No. 15-474 (D. Del.); (2) Novartis Pharm. Corp. et al. v. Par Pharm., Inc., No. 15-1050 (D. Del.); (3) Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-00074 (P.T.A.B.) (U.S. Patent No. 7,741,338, Order Terminating Proceeding filed April 1, 2016); (4) Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-00075 (P.T.A.B.) (U.S. Patent No. 7,297,703, Order Terminating Proceeding filed April 1, 2016); and (5) Novartis AG v. Par Pharm., Inc., *Inter Partes* Review No. 2016-00078 (P.T.A.B.) (U.S. Patent No. 6,455,518, Decision Denying Institution filed April 28, 2016).

**IDENTIFICATION OF LEAD AND BACK-UP COUNSEL
PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10**

The lead counsel information has not changed.

The Patent Owner hereby notifies the Board that it is adding attorney of record Peter J. Waibel (Registration No. 43,228) and Christina Schwarz (admitted *pro hac vice*) as additional back-up counsel. All other counsel information remains the same.

Additional back-up counsel:

Peter J. Waibel (Registration No. 43,228)
NOVARTIS PHARMACEUTICALS CORPORATION
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080
Tel. 862-778-7838

Christina Schwarz
FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100
cschwarz@fchs.com

An updated power of attorney with the updated designation of counsel is being submitted with this Notice.

SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)

The service information has not changed.

Respectfully submitted,

Dated: July 12, 2016

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
Lead Counsel for Patent Owner

FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.